Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBESUA)

Drug Name
Tucatinib Drug Info
Synonyms
Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
Indication
Disease Entry ICD 11 Status REF
HER2-positive breast cancer 2C60-2C65 Approved [1]
Gastric adenocarcinoma 2B72 Phase 2/3 [2]
Cross-matching ID
PubChem CID
51039094
CAS Number
CAS 937263-43-9
TTD Drug ID
DMBESUA
ACDINA Drug ID
D01510

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [4]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [5]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [6]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [7]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [8]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [9]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [10]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [11]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [12]
HKI-272 DM6QOVN Breast cancer 2C60-2C65 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
UDP-glucuronosyltransferase 1-6 OTGTQ2C9 UD16_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A1 OTH1C8OJ UD11_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A10 OTOTZVEY UD110_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A3 OTUEOER3 UD13_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A7 OTY4JJ32 UD17_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A8 OTTMABBG UD18_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 1A9 OTPCHAFX UD19_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 2B15 OTABTFU2 UDB15_HUMAN Gene/Protein Processing [3]
UDP-glucuronosyltransferase 2B17 OTSVIF4E UDB17_HUMAN Gene/Protein Processing [3]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
3 Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. Chem Biol Interact. 2023 Aug 25;381:110574. doi: 10.1016/j.cbi.2023.110574. Epub 2023 May 30.
4 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
6 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
7 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
11 Clinical pipeline report, company report or official report of Roche (2009).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.